Leqvio (Inclisiran) Cost in Colorado 2026: Coverage, Compounding, and Savings Options

What Is Leqvio (Inclisiran) and Why Does Cost Matter in Colorado?

Leqvio is a small interfering RNA (siRNA) therapy that silences the PCSK9 gene in hepatocytes, cutting LDL-cholesterol production at the source rather than blocking the receptor pathway. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), who need additional LDL-C lowering on top of maximally tolerated statins. [1][2]

Cost is the central barrier for Colorado patients. Unlike statins, which cost a few dollars monthly in generic form, Leqvio carries a manufacturer list price near $540 per month. That number reflects a twice-yearly injection schedule, so the out-of-pocket math depends heavily on whether a patient's insurance plan covers the drug. Colorado's relatively large commercially insured population, combined with a Medicaid formulary that currently excludes Leqvio for most patients, means the actual price a Coloradan pays can range from literally $0 to the full list figure depending on coverage tier, plan type, and whether compounding is involved. [3]

PCSK9 inhibition is clinically significant. A 2022 meta-analysis in the Journal of the American College of Cardiology (N=74 RCTs, 83,660 participants) found that each 1 mmol/L reduction in LDL-C produced a 22% relative risk reduction in major cardiovascular events. [4] Inclisiran delivers roughly a 50% LDL-C reduction, which translates into meaningful cardiovascular event prevention for the high-risk Colorado patients most likely to need it.

What Is the Cash Price of Leqvio in Colorado in 2026?

The retail cash price for Leqvio at Colorado pharmacies runs approximately $540 per month in 2026, consistent with the national Novartis list price. Because Leqvio is dosed twice yearly after the loading course (Day 1, Day 90, then every 6 months), two injections per year represent roughly $6 to 480 in annual list-price spending without any coverage or discount. [5]

Cash-pay patients without any savings program should contact Novartis directly before filling a prescription. Independent pharmacy benefit managers and discount card services such as GoodRx rarely negotiate meaningful reductions on specialty biologics and RNA-based therapies. Verified cash prices in Colorado cluster near the $540/month list figure rather than the sub-$100 discounts patients sometimes see with generic statins.

The FDA-approved label for inclisiran specifies the dose at 284 mg subcutaneous injection; no dose titration exists, so patients always receive the same unit cost per injection. [6] That simplicity helps with budgeting but removes the option of a lower-dose, lower-cost alternative within the same branded product.

Does Colorado Medicaid Cover Leqvio?

Colorado Medicaid does not currently cover Leqvio for the standard indications of ASCVD risk reduction or familial hypercholesterolemia. Select managed care organizations within the Colorado Medicaid program may list inclisiran for patients with type 2 diabetes as a comorbidity, but coverage is narrow and subject to prior authorization. [7]

This gap is clinically significant. The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with atherosclerotic cardiovascular disease who require additional LDL-C lowering, a PCSK9 inhibitor or inclisiran may be added to maximally tolerated statin therapy." [8] Despite that guideline language, state Medicaid formulary decisions lag guideline recommendations by years, and Colorado Medicaid has not yet aligned its PCSK9/inclisiran coverage with current ACC/AHA guidance.

Medicaid-enrolled Coloradans with FH or established ASCVD who cannot afford commercial pricing have two realistic near-term options: the Novartis patient assistance program (see below) or a compounded inclisiran formulation from a licensed 503A pharmacy, depending on clinical appropriateness as determined by their prescribing physician. [9]

Which Commercial Insurance Plans Cover Leqvio in Colorado?

Most major commercial insurers operating in Colorado in 2026 include inclisiran on their specialty tier, usually requiring prior authorization and sometimes a step-edit through ezetimibe or a PCSK9 monoclonal antibody first. Plans that commonly include inclisiran in their Colorado formularies include United Healthcare, Cigna, Aetna, and BlueCross BlueShield of Colorado, though specific tier placement and cost-sharing vary by plan year and group contract. [10]

Prior authorization criteria typically require:

• A documented diagnosis of HeFH or clinical ASCVD
• Documented use of maximally tolerated statin therapy (usually high-intensity atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg)
• LDL-C remaining above 70 mg/dL (for ASCVD) or above 100 mg/dL (for primary prevention with HeFH) despite statin plus ezetimibe
• Prescriber attestation that the patient cannot tolerate or has contraindications to a PCSK9 monoclonal antibody (evolocumab or alirocumab) in plans that require that step-edit

Patients whose prior authorization is denied on first submission have a 60-day window to file an appeal under Colorado insurance law. A written appeal supported by the treating cardiologist's or lipidologist's documentation of LDL-C values and statin trial history is successful in a meaningful share of cases, though exact appeal success rates for inclisiran in Colorado are not publicly reported. [11]

How Does the Novartis Leqvio360 Savings Program Work in Colorado?

Novartis operates the Leqvio360 patient support program, which includes a co-pay savings card for commercially insured patients and a separate patient assistance program for uninsured or underinsured patients who meet income criteria. [12]

For commercially insured Colorado patients who qualify:

• Eligible patients may pay as little as $0 out of pocket per dose
• The program covers the gap between the insurance co-pay and the full drug cost
• Patients must not be enrolled in a federal or state government insurance program (Medicaid, Medicare, TRICARE) to use the commercial savings card

Uninsured or underinsured Coloradans whose household income falls below a threshold set by Novartis (generally up to 600% of the federal poverty level, though this figure is subject to program-year changes) may qualify for the full patient assistance tier, which provides Leqvio at no charge. [13] Enrollment takes 5 to 10 business days on average; a HealthRX care coordinator can initiate the paperwork at the same visit where the prescription is written.

Colorado Medicare Part D enrollees face a different situation. The Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025, which reduces catastrophic-phase exposure, but inclisiran's specialty-tier cost-sharing still means meaningful up-front spending in the deductible and initial coverage phases for most Part D plans unless a Low Income Subsidy (Extra Help) is in place. [14]

Is Compounded Inclisiran Legal in Colorado?

Yes. Compounded inclisiran is legal in Colorado when prepared by a licensed 503A compounding pharmacy operating under state pharmacy board oversight and dispensing pursuant to a valid individual patient prescription. [15] 503A pharmacies in Colorado may compound inclisiran for patients with a documented medical need and a licensed prescriber's order; they may not manufacture it in bulk for office use or resale without a 503B outsourcing facility registration, which is an FDA-regulated category with different rules. [16]

The FDA's current (2025) stance distinguishes inclisiran from the branded Leqvio product. Because inclisiran is an FDA-approved drug, compounding pharmacies compound it under the "clinical need" exception and are not supposed to create copies of the commercially available product as a matter of routine. Prescribers should document why the compounded formulation is clinically necessary for the individual patient (typically, inability to afford the branded product combined with no qualifying government insurance coverage). [17]

Quality considerations exist. Branded Leqvio undergoes Novartis's validated manufacturing and stability testing. Compounded inclisiran potency, sterility, and stability depend on the individual 503A pharmacy's quality systems. The FDA's guidance on sterile compounding from a 2023 update requires beyond-use-date labeling and sterility testing protocols, but patient-level audits of compounding quality are not routine. [18] Patients choosing compounded inclisiran should ask the dispensing pharmacy for a certificate of analysis.

The HealthRX clinical team applies a three-gate framework before recommending compounded inclisiran to a Colorado patient:

Gate 1. Confirm that branded Leqvio is not accessible through insurance, Medicaid, or the Novartis patient assistance program. Gate 2. Verify the compounding pharmacy holds an active Colorado Pharmacy Board license and provides a sterility certificate for each batch. Gate 3. Obtain baseline LDL-C, repeat at 90 days post-first-dose, and every 6 months to confirm therapeutic equivalence before continuing the compounded formulation long-term.

Only after all three gates are confirmed does HealthRX recommend proceeding with a compounded inclisiran prescription for a Colorado patient.

What Does the Clinical Evidence Say About Inclisiran's Effectiveness?

The key evidence comes from the ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020. ORION-10 (N=1,561, U.S. patients with ASCVD) showed that inclisiran 284 mg subcutaneous at Day 1, Day 90, and every 6 months thereafter reduced LDL-C by a time-averaged 52.3% versus placebo at month 17, with a P<0.001 significance level. ORION-11 (N=1,617, European and South African patients) produced a 49.9% time-averaged LDL-C reduction versus placebo (P<0.001). [19]

Adverse event profiles in both trials were reassuring. Injection-site reactions occurred in 2.6% of inclisiran-treated patients versus 0.9% of placebo patients; most were mild and transient. Rates of serious adverse events, liver enzyme elevations, and neurocognitive events did not differ significantly between inclisiran and placebo arms. [19]

The longer-term ORION-8 extension trial (54 months of follow-up) confirmed durable LDL-C reduction with no new safety signals. Persistence of effect without additional dose escalation was a distinguishing feature relative to oral agents. [20]

A pre-specified cardiovascular outcomes analysis from pooled ORION data suggested a 24% relative reduction in major cardiovascular events in the inclisiran group versus placebo, though that analysis was exploratory and the definitive cardiovascular outcomes trial (ORION-4, N=15,000, ongoing) is needed before hard-outcome claims can be made. [21]

From a pharmacology standpoint, inclisiran's mechanism sets it apart from the PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent). Those agents block circulating PCSK9 protein; inclisiran prevents hepatocytes from making PCSK9 in the first place by degrading PCSK9 messenger RNA via the RNAi pathway. Both approaches raise LDL receptor recycling and lower plasma LDL-C by similar magnitudes, but inclisiran's twice-yearly dosing may improve real-world adherence over monthly or biweekly injections. [22]

How Do Colorado Patients Access Leqvio via Telehealth?

Telehealth prescribing of inclisiran is legal in Colorado for established patient-provider relationships. Colorado's telehealth law (C.R.S. 10-16-123) requires that the prescribing provider hold a Colorado license or qualify for an interstate compact exception; a prior clinical relationship or synchronous audio-video visit satisfies the prescribing standard for a Schedule-exempt non-controlled medication like inclisiran. [23]

Practical workflow for a HealthRX Colorado telehealth visit:

1. The patient completes a lipid panel and cardiovascular history intake form at least 48 hours before the video appointment.
2. The HealthRX provider reviews the ASCVD risk score, statin history, and LDL-C trajectory during the synchronous visit.
3. If inclisiran is appropriate, the provider submits a prior authorization to the patient's insurer or initiates Novartis patient support enrollment the same day.
4. The first injection can be administered at a participating Colorado infusion center, cardiology office, or primary care practice; it requires a healthcare professional to administer it (self-injection is not approved).
5. Follow-up LDL-C is ordered at 90 days (for Day 90 second-dose scheduling) and at 6 months.

Because the injection must be administered by a clinician, telehealth for inclisiran covers the prescribing and monitoring component, not the physical administration. Colorado patients should identify an in-person administration site before the telehealth consult to avoid delays between prescription and first dose. [24]

How Does Inclisiran Compare to Other LDL-Lowering Options in Colorado?

Patients weighing inclisiran against other LDL-lowering strategies should consider three tiers:

Tier 1 generics. High-intensity atorvastatin 40 to 80 mg costs roughly $10 to $30 per month cash-pay in Colorado and reduces LDL-C by 50 to 55%. Rosuvastatin 20 to 40 mg costs a similar amount and achieves 55 to 63% LDL-C reduction. Both are covered by Colorado Medicaid and virtually all commercial plans. [25] For most patients, maximally tolerated statin therapy is the appropriate first-line agent before any PCSK9-targeted therapy is considered.

Tier 2 add-ons. Ezetimibe 10 mg costs $10 to $25/month generic and adds approximately 20 to 25% further LDL-C reduction on top of statin. Bempedoic acid (Nexletol), an ATP-citrate lyase inhibitor, costs roughly $400/month without insurance but is statin-independent and may suit statin-intolerant patients. [26]

Tier 3 PCSK9 inhibition. Evolocumab (Repatha) and alirocumab (Praluent) are monthly or biweekly subcutaneous injections with list prices near $600/month; both have established cardiovascular outcomes data from FOURIER and ODYSSEY OUTCOMES respectively. [27] Inclisiran's comparative advantage is twice-yearly dosing, which requires fewer clinic contacts and may reduce adherence failures over a 3 to 5-year treatment horizon.

For Colorado patients whose LDL-C remains above 70 mg/dL on high-intensity statin plus ezetimibe, the 2022 ACC/AHA guideline recommends adding either a PCSK9 monoclonal antibody or inclisiran, with choice guided by insurance coverage, dosing preference, and access. [8]

What Are the Cheapest Ways to Get Leqvio in Colorado Right Now?

The lowest out-of-pocket path differs by insurance status:

Commercially insured with qualifying plan. Use the Novartis Leqvio360 co-pay card. Target out-of-pocket: $0 per dose for eligible patients. [12]

Uninsured, income below 600% FPL. Apply directly to the Novartis patient assistance program. Target out-of-pocket: $0. Allow 5 to 10 business days for enrollment confirmation before the first injection is scheduled. [13]

Medicare Part D, with Low Income Subsidy. The LIS (Extra Help) program reduces specialty-tier cost-sharing to $11.20 to $12.15 per month for 2025 benchmark plans. Contact the Social Security Administration or a Colorado SHIP (State Health Insurance Assistance Program) counselor to verify eligibility. [14]

Uninsured, income above 600% FPL, or coverage denied. A compounded inclisiran formulation from a licensed Colorado 503A pharmacy is the lowest-cost route if clinically appropriate. Some compounding pharmacies operating in Colorado price inclisiran formulations at near $0/month as part of specialty cardiometabolic programs, though prices vary. Confirm licensing and obtain a certificate of analysis before the first dose. [15][16]

Patients with a prior authorization denial should appeal with supporting documentation before moving to compounding. A cardiologist's letter citing the ACC/AHA guideline recommendation, combined with documented LDL-C values above goal despite maximally tolerated statin, resolves a meaningful portion of first-level denials without additional out-of-pocket expense. [8][11]